Avidence Therapeutics

Avidence Therapeutics is a New York-based biotechnology company focused on developing next-generation regenerative medicines and long-acting injectable (LAI) therapies. Founded in 2018 and operating out of Harlem Biospace, the company leverages a proprietary platform that integrates microsphere and nanoparticle technology to optimize drug delivery for chronic musculoskeletal and metabolic conditions. Their lead programs include disease-modifying treatments for osteoarthritis and degenerative disc disease, as well as extended-release formulations of validated agents like rofecoxib and tirzepatide. By modulating cellular microenvironments and regenerative pathways, Avidence aims to provide superior clinical efficacy and safety compared to traditional standards of care. The company operates as a private entity and is actively advancing its pipeline toward clinical-stage development.